Abstract
Long-term follow-up of intravesical gemcitabine and docetaxel as rescue therapy for nonmuscle-invasive bladder cancer
Journal of clinical oncology, Vol.40(6_suppl), pp.573-573
02/20/2022
DOI: 10.1200/JCO.2022.40.6_suppl.573
Abstract
573
Background: Intravesical bacillus Calmette-Guérin (BCG) is the first-line treatment for high-risk non-muscle invasive bladder cancer (NMIBC). Unfortunately, disease recurrence/progression is common and associated with increased risk of death from bladder cancer. While radical cystectomy remains the preferred treatment for BCG unresponsive NMIBC, many patients are either unwilling or unfit to undergo surgery. Previous retrospective studies have demonstrated the efficacy of intravesical gemcitabine and docetaxel (Gem/Doce) for treating NMIBC after BCG failure. However, the long-term outcomes of this cohort are unknown. We report 5-year survival outcomes of patients treated with intravesical Gem/Doce after BCG failure. Methods: We retrospectively identified patients at our institution who were treated with Gem/Doce for high-risk NMIBC after BCG failure between 2009 and 2017. Patients received six weekly intravesical Gem/Doce instillations. Initial responders received monthly maintenance instillations for 2 years. Surveillance was performed according to American Urological Association guidelines. Survival time was measured from start of Gem/Doce induction. Outcomes included high-grade recurrence-free survival (HG-RFS), progression-free survival (PFS), cystectomy-free survival (CFS), cancer-specific survival (CSS) and overall survival (OS). Recurrence was defined as pathologically confirmed tumor relapse in the bladder or prostatic urethra. Progression was defined as recurrence of disease with stage T2 or greater, cystectomy or death due to bladder cancer. Survival probabilities were calculated with the Kaplan-Meier method. Results: A total of 97 patients with a median age of 73 years were treated with Gem/Doce after BCG failure. Median follow-up was 49 months. BCG failure was further stratified as BCG unresponsive (35%), BCG relapsing (38%), BCG intolerant (11%) or unspecified (16%). 71% and 21% of patients had carcinoma in-situ and high-grade T1 disease, respectively. Complete response at initial surveillance was 74% and median duration of response was 26 months. Overall HG-RFS at 1, 2 and 5 years was 60%, 51% and 31%, respectively. HG-RFS was similar among BCG unresponsive patients and the overall cohort (see table). During follow-up, 18 patients (19%) underwent radical cystectomy and 28 patients (29%) experienced disease progression. PFS, CFS, CSS and OS at 5 years was 68%, 75%, 91% and 64%, respectively. Conclusions: Intravesical Gem/Doce for high-risk NMIBC after BCG failure offers long-term efficacy and substantial durability of response with a high likelihood of bladder preservation at five years after induction. Future prospective trials assessing Gem/Doce are warranted.[Table: see text]
Details
- Title: Subtitle
- Long-term follow-up of intravesical gemcitabine and docetaxel as rescue therapy for nonmuscle-invasive bladder cancer
- Creators
- Phani T. Chevuru - University of IowaIan Mitchell McElree - Roy J. and Lucille A. Carver College of MedicineAlexander C. Martin - University of IowaJordan Richards - University of IowaSarah L. Mott - University of IowaPaul T. Gellhaus - University of IowaKenneth G. Nepple - University of IowaRyan L. Steinberg - University of IowaMichael A. O'Donnell - University of IowaVignesh T. Packiam - University of Iowa
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.40(6_suppl), pp.573-573
- DOI
- 10.1200/JCO.2022.40.6_suppl.573
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Grant note
- name: John & Carol Walter Family Foundation; DOI: 10.13039/100015515, name: Carver College of Medicine.
- Language
- English
- Date published
- 02/20/2022
- Academic Unit
- Urology; Surgery
- Record Identifier
- 9984321436202771
Metrics
9 Record Views